Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
The purpose of this study was to determine the prognostic impact of fat loss after immune checkpoint inhibitor (ICI) treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC). Data from 60 patients treated with ICI therapy for metastatic ccRCC were retrospectively analyzed. Chang...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/4/3994 |
| _version_ | 1797620386545795072 |
|---|---|
| author | Ji Hyun Lee Soohyun Hwang ByulA Jee Jae-Hun Kim Jihwan Lee Jae Hoon Chung Wan Song Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Se Hoon Park Ghee Young Kwon Minyong Kang |
| author_facet | Ji Hyun Lee Soohyun Hwang ByulA Jee Jae-Hun Kim Jihwan Lee Jae Hoon Chung Wan Song Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Se Hoon Park Ghee Young Kwon Minyong Kang |
| author_sort | Ji Hyun Lee |
| collection | DOAJ |
| description | The purpose of this study was to determine the prognostic impact of fat loss after immune checkpoint inhibitor (ICI) treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC). Data from 60 patients treated with ICI therapy for metastatic ccRCC were retrospectively analyzed. Changes in cross-sectional areas of subcutaneous fat (SF) between the pre-treatment and post-treatment abdominal computed tomography (CT) images were expressed as percentages and were divided by the interval between the CT scans to calculate ΔSF (%/month). SF loss was defined as ΔSF < −5%/month. Survival analyses for overall survival (OS) and progression-free survival (PFS) were performed. Patients with SF loss had shorter OS (median, 9.5 months vs. not reached; <i>p</i> < 0.001) and PFS (median, 2.6 months vs. 33.5 months; <i>p</i> < 0.001) than patients without SF loss. ΔSF was independently associated with OS (adjusted hazard ratio (HR), 1.49; 95% confidence interval (CI), 1.07–2.07; <i>p</i> = 0.020) and PFS (adjusted HR, 1.57; 95% CI, 1.17–2.12; <i>p</i> = 0.003), with a 5%/month decrease in SF increasing the risk of death and progression by 49% and 57%, respectively. In conclusion, Loss of SF after treatment initiation is a significant and independent poor prognostic factor for OS and PFS in patients with metastatic ccRCC who receive ICI therapy. |
| first_indexed | 2024-03-11T08:40:30Z |
| format | Article |
| id | doaj.art-25b23c6415514ce1a88144858eadb47a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T08:40:30Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-25b23c6415514ce1a88144858eadb47a2023-11-16T21:07:57ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01244399410.3390/ijms24043994Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsJi Hyun Lee0Soohyun Hwang1ByulA Jee2Jae-Hun Kim3Jihwan Lee4Jae Hoon Chung5Wan Song6Hyun Hwan Sung7Hwang Gyun Jeon8Byong Chang Jeong9Seong Il Seo10Seong Soo Jeon11Hyun Moo Lee12Se Hoon Park13Ghee Young Kwon14Minyong Kang15Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of KoreaDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaDivision of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of KoreaDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of KoreaDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of KoreaThe purpose of this study was to determine the prognostic impact of fat loss after immune checkpoint inhibitor (ICI) treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC). Data from 60 patients treated with ICI therapy for metastatic ccRCC were retrospectively analyzed. Changes in cross-sectional areas of subcutaneous fat (SF) between the pre-treatment and post-treatment abdominal computed tomography (CT) images were expressed as percentages and were divided by the interval between the CT scans to calculate ΔSF (%/month). SF loss was defined as ΔSF < −5%/month. Survival analyses for overall survival (OS) and progression-free survival (PFS) were performed. Patients with SF loss had shorter OS (median, 9.5 months vs. not reached; <i>p</i> < 0.001) and PFS (median, 2.6 months vs. 33.5 months; <i>p</i> < 0.001) than patients without SF loss. ΔSF was independently associated with OS (adjusted hazard ratio (HR), 1.49; 95% confidence interval (CI), 1.07–2.07; <i>p</i> = 0.020) and PFS (adjusted HR, 1.57; 95% CI, 1.17–2.12; <i>p</i> = 0.003), with a 5%/month decrease in SF increasing the risk of death and progression by 49% and 57%, respectively. In conclusion, Loss of SF after treatment initiation is a significant and independent poor prognostic factor for OS and PFS in patients with metastatic ccRCC who receive ICI therapy.https://www.mdpi.com/1422-0067/24/4/3994immunotherapytumor biomarkerskidney neoplasmstumor microenvironment |
| spellingShingle | Ji Hyun Lee Soohyun Hwang ByulA Jee Jae-Hun Kim Jihwan Lee Jae Hoon Chung Wan Song Hyun Hwan Sung Hwang Gyun Jeon Byong Chang Jeong Seong Il Seo Seong Soo Jeon Hyun Moo Lee Se Hoon Park Ghee Young Kwon Minyong Kang Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors International Journal of Molecular Sciences immunotherapy tumor biomarkers kidney neoplasms tumor microenvironment |
| title | Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| title_full | Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| title_fullStr | Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| title_full_unstemmed | Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| title_short | Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| title_sort | fat loss in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitors |
| topic | immunotherapy tumor biomarkers kidney neoplasms tumor microenvironment |
| url | https://www.mdpi.com/1422-0067/24/4/3994 |
| work_keys_str_mv | AT jihyunlee fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT soohyunhwang fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT byulajee fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT jaehunkim fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT jihwanlee fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT jaehoonchung fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT wansong fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT hyunhwansung fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT hwanggyunjeon fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT byongchangjeong fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT seongilseo fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT seongsoojeon fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT hyunmoolee fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT sehoonpark fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT gheeyoungkwon fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors AT minyongkang fatlossinpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithimmunecheckpointinhibitors |